| [1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| [2] |
Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol, 2013, 31(9): 1188-1195.
|
| [3] |
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6): 1268-1289.
|
| [4] |
Guro H, Kim JW, Choi Y, et al. Multidisciplinary management of intrahepatic cholangiocarcinoma: current approaches[J]. Surg Oncol, 2017, 26(2): 146-152.
|
| [5] |
Lee Y, Yoo IR, Boo SH, et al. The role of F-18 FDG PET/CT in intrahepatic cholangiocarcinoma[J]. Nucl Med Mol Imaging, 2017, 51(1): 69-78.
|
| [6] |
Lo EC, Rucker AN, Federle MP. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma: imaging for diagnosis, tumor response to treatment and liver response to radiation[J]. Semin Radiat Oncol, 2018, 28(4): 267-276.
|
| [7] |
Waisberg DR, Pinheiro RS, Nacif LS, et al. Resection for intrahepatic cholangiocellular cancer: new advances[J]. Transl Gastroenterol Hepatol, 2018(3): 60.
|
| [8] |
de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment[J]. J Clin Oncol, 2011, 29(23): 3140-3145.
|
| [9] |
Kang SH, Hwang S, Lee YJ, et al. Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2018, 25(4): 240-248.
|
| [10] |
Levy MJ, Heimbach JK, Gores GJ. Endoscopic ultrasound staging of cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2012, 28(3): 244-252.
|
| [11] |
Ma KW, Cheung TT, She WH, et al. The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma: a single-center experience[J]. Medicine, 2016, 95(28): e4133.
|
| [12] |
Spolverato G, Yakoob MY, Kim Y, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(12): 4020-4028.
|
| [13] |
Murakami S, Ajiki T, Okazaki T, et al. Factors affecting survival after resection of intrahepatic cholangiocarcinoma[J]. Surg Today, 2014, 44(10): 1847-1854.
|
| [14] |
Chang ME, Lei HJ, Chen MH, et al. Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center[J]. J Chin Med Assoc, 2017, 80(3): 140-146.
|
| [15] |
Squires MH, Cloyd JM, Dillhoff M, et al. Challenges of surgical management of intrahepatic cholangiocarcinoma[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(7): 671-681.
|
| [16] |
Reames BN, Ejaz A, Koerkamp BG, et al. Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis[J]. J Surg Oncol, 2017, 116(2): 133-139.
|
| [17] |
Schadde E, Raptis DA, Schnitzbauer AA, et al. Prediction of mortality after ALPPS stage-1: an analysis of 320 patients from the International ALPPS Registry[J]. Ann Surg, 2015, 262(5): 780-785.
|
| [18] |
Goere D, Wagholikar GD, Pessaux P, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma[J]. Surg Endosc, 2006, 20(5): 721-725.
|
| [19] |
Razumilava N, Gores GJ. Cholangiocarcinoma[J]. Lancet, 2014, 383(9935): 2168-2179.
|
| [20] |
Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4): 1178-1188.
|
| [21] |
Zhang SJ, Hu P, Wang N, et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2013, 20(11): 3596-3602.
|
| [22] |
Fu Y, Yang W, Wu W, et al. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma[J].J Vasc Interv Radiol, 2012, 23(5): 642-649.
|
| [23] |
Ma KW, Cheung TT, Leung B, et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis[J]. Medicine, 2019, 98(5): e14013.
|
| [24] |
Ray CE Jr, Edwards A, Smith MT, et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma[J]. J Vasc Interv Radiol, 2013, 24(8): 1218-1226.
|
| [25] |
Al-Adra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis[J]. Eur J Surg Oncol, 2015, 41(1): 120-127.
|
| [26] |
Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy isa promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment[J]. Ann Surg Oncol, 2015, 22(9): 3102-3108.
|
| [27] |
Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2015, 111(2): 213-220.
|
| [28] |
Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis[J]. J Clin Oncol, 2016, 34(3): 219-226.
|
| [29] |
Shinohara ET, Mitra N, Guo M, et al. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1495-1501.
|
| [30] |
Jiang W, Zeng ZC, Tang ZY, et al. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases[J]. J Cancer Res Clin Oncol, 2010, 136(9): 1323-1331.
|
| [31] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281.
|
| [32] |
Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial[J]. Lancet Oncol, 2015, 16(8): 967-978.
|
| [33] |
Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial[J]. Lancet Oncol, 2014, 15(8): 819-828.
|
| [34] |
Rogers JE, Law L, Nguyen VD, et al. Second-line systemic treatment for advanced cholangiocarcinoma[J]. J Gastrointest Oncol, 2014, 5(6): 408-413.
|
| [35] |
Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7): 839-847.
|
| [36] |
Jain A, Kwong LN, Javle M. Genomic profiling of biliary tract cancers and implications for clinical practice[J]. Curr Treat Options Oncol, 2016, 17(11): 58.
|
| [37] |
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer[J]. Science, 2014, 344(6184): 641-645.
|
| [38] |
Sur MD, In H, Sharpe SM, et al. Defining the benefit of adjuvant therapy following resection for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22(7): 2209-2217.
|
| [39] |
Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline[J].J Clin Oncol, 2019, 37(2): 1015-1027.
|